

Type 2 Diabetes Mellitus – What to do When Monotherapy Fails.

Julie C. Oki, PharmD, BCPS

November 20, 1997

Slides for this lecture can be found on the internet at:

http://ctr.umkc.edu/user/umkcmedpharm/section/CORE_CUR/TYPE2DM/index.htm

SELECTED REFERENCES:

Combination therapy review:

- White JR. Combination oral agent/insulin therapy in patients with type 2 diabetes mellitus. Clin Diabetes May/June 1997; 102-112.

Acarbose

- Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46:1025-54.
- Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98:443-51.
- Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928-35.
- Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154:2442-8.
- Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefebvre PJ. Reduction of the acute bioavailability of metformin by the α -glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24 (Suppl 3):50-4.
- Baron A, Neumann C. PROTECT interim results: a large multicenter study of patients with Type II diabetes. Clinical Therapeutics 1997; March/April:282-295.

Metformin

- Dunn CJ, Peters DH. Metformin: A review of its pharmacologic properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49:721-49.
- Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-72
- Defronzo RA, Goodman AM, and The Multicenter Metformin Study Group. Efficacy of metformin inpatients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-549.
- Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:555-60.
- Garber AJ. Metformin dose-response study in patients with type 2 diabetes. Am J Med (in press).

Oral Sulfonylureas

- Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
- Rosenstock J, Samols E, Muchmore DB, Schneider J for The Glimpiride Study Group. Glimpiride, a new once-daily sulfonylurea. Diabetes Care 1996; 19:1194-1199.

Troglitazone

- Parke Davis. Rezulin® package insert. Morris Plains, NJ; 1997 October.
- Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes mellitus. Diabetes 1996; 45:1661-1669.
- Yosuhiko I, Kosaka K, Kuzuya T, et al. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156.

Combination Therapy with Insulin and Oral Sulfonylureas

- Pugh JA, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. *Diabetes Care* 1992; 15:953-9.
- Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. *Ann Intern Med* 1991; 115:45-53.
- Riddle MC, Hart JS, Bouma DJ, et al. Efficacy of bedtime insulin with daytime sulfonylurea for subpopulation of Type II diabetic subjects. *Diabetes Care* 1989; 12:623-29.
- Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med* 1992; 327:1426-33.
- Riddle MC. Combined insulin and sulfonylurea therapy: a practical way to start insulin therapy for people with NIDDM. *Clinical Diabetes* 1994; May/June:57-64.
- Shank ML, Del Prat S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. *Diabetes* 1995; 44:165-72.

Insulin Therapy

- Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Applications, benefits, and risks. *Diabetes Reviews* 1995; 3:308-34.

ADA Consensus Statements

- American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDDM (Consensus Statement). *Diabetes Care* 1995; 18:1510-18.
- American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20:1183-97.

Pathophysiology of NIDDM

- DeFronzo, RA. The triumvirate: β -cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes* 1988; 667-87.
- Polonsky KS, Jeppe S, Bell GI. Non-insulin-dependent diabetes mellitus--a genetically programmed failure of the beta cell to compensate for insulin resistance. *N Engl J Med* 1996; 334:777-783.